Health Care Law Institute 2015

Front Matter
Faculty Bios
Table of Contents
Chapter 1. Reimbursement Policies for Biosimilars (September 4, 2015)
Chapter 2. CMS MLN Matters® Number: SE1509, Food and Drug Administration Approval of First Biosimilar Product (March 2015)
Chapter 3. The Future Cost of Innovation: An Analysis of the Impact of Breakthrough Therapies on Government Spending (June 2015)
Chapter 4. Medicare Advantage: 2015 National Snapshot (July 2015)
Chapter 5. Clinical Pathways: Overview of Current Practices and Potential Implications for Patients, Payers, and Providers (July 2015)
Chapter 6. Providers Rush to Assume Medicare Risk under Bundled Payment Program: Orthopedic, Pulmonary, and Cardiovascular Conditions Most Likely To Be Treated under CMS Bundled Payment Program
Chapter 7. New Market Entrants: Growth and Diversification in U.S. Health Insurance (September 2015)
Chapter 8. More than 2 Million Exchange Enrollees Forgo Cost-Sharing Assistance
Chapter 9. Excerpt: Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2016: Proposed Rule by the Centers for Medicare & Medicaid Services on 07/15/2015
Chapter 10. Department of Health and Human Services, Centers for Medicare & Medicaid Services, Medicare Program; Medicare Shared Savings Program: Accountable Care Organizations; Final Rule, 76 F.R. 212, Wednesday, November 2, 2011, Part III
Chapter 11. Financial Models to Support State Efforts to Integrate Care for Medicare-Medicaid Enrollees
Chapter 12. Current Enforcements Trends in Healthcare (PowerPoint slides)
Chapter 13. 2015 Mid-Year FDA and Health Care Compliance and Enforcement Update—Drugs and Devices
Chapter 14. Developing Mixed-Source Commercial Products: Open Source Software Risks and Mitigation
Chapter 15. Compliance Programs and Investigations (PowerPoint slides)
Chapter 16. Practical Guidance for Health Care Governing Boards on Compliance Oversight
Chapter 17. Updated: OIG’s Provider Self-Disclosure Protocol
Chapter 18. Department of Health and Human Services, Office of Inspector General, Publication of OIG Compliance Program Guidance for Clinical Laboratories
Chapter 19. CMS Voluntary Self-Referral Disclosure Protocol
Chapter 20. Department of Health and Human Services, Office of Inspector General, Publication of the OIG Compliance Program Guidance for Hospitals
Chapter 21. Department of Health and Human Services, Office of Inspector General, OIG Supplemental Compliance Program Guidance for Hospitals
Chapter 22. 21st Century Cures Act: Key Provisions Related to Drugs (August 7, 2015)
Chapter 23. 21st Century Cures Act: Key Provisions Related to Medical Devices (July 30, 2015)
Index